Dian Diagnostics stock experiences unusual trading volatility

Dian Diagnostics Group (SZSE:300244) has announced that its stock experienced abnormal trading fluctuations, with a cumulative deviation of over 30% in the past three trading days. The company's board of directors has confirmed that there are no undisclosed significant matters or strategic developments that should have been disclosed. The company also reiterated its prior earnings forecast for 2024, projecting a net loss attributable to shareholders of between 270 million to 370 million RMB. Dian Diagnostics has advised investors to exercise caution and rely on official announcements through designated media outlets.